Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2004; 91(03): 628-630DOI: 10.1055/s-0037-1614288 Letters to the Editor Schattauer GmbH Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study) Authors Constantine Konstantoulas Emma Hawe Naomi Saut John S. Yudkin Giovanni di Minno Maurizio Margaglione Anders Hamsten Steve E. Humphries Irene Juhan-Vague Helen Ireland behalf of the HIFMECH Study Group Recommend Article Abstract Buy Article(opens in new window) Full Text References References 1 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257 (14) 7944-7. 2 Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258 (20) 12238-42. 3 Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477 1-2 349-60. 4 Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29 (Suppl. 07) S48-S51. 5 Ireland H, Kyriakoulis K, Kunz G. et al. Directed search for thrombomodulin gene mutations. Haemostasis 1996; 26 (Suppl. 04) 227-32. 6 Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997; 78 (01) 396-400. 7 Norlund L, Zoller B, Ohlin AK. A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis. Thromb Haemost 1997; 78 (04) 1164-6. 8 van der Velden PA, Krommenhoek-Van EsT, Al-laart CF. et al. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb Haemost 1991; 65 (05) 511-3. 9 Hayashi T, Zushi M, Yamamoto S. et al. Further localization of binding sites for thrombin and protein C in human thrombomodulin. J Biol Chem 1990; 265 (33) 20156-9. 10 Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cefaclor activity. J Biol Chem 1992; 267 (09) 6164-70. 11 Wu KK, Aleksic N, Ahn C. et al. Thrombomodulin Ala455 Val polymorphism and risk of coronary heart disease. Circulation 2001; 103 (10) 1386-9. 12 Norlund L, Holm J, Zoller B. et al. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997; 77 (02) 248-51. 13 Le Flem L, Mennen L, Aubry ML. et al. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler Thromb Vase Biol 2001; 21 (03) 445-51. 14 Dittman WA, Nelson SC, Greer PK. et al. Characterization of thrombomodulin expression in response to retinoic acid and identification of a retinoic acid response element in the human thrombomodulin gene. J Biol Chem 1994; 269 (24) 16925-32. 15 Yu K, Morioka H, Fritze LM. et al. Transcriptional regulation of the thrombomodulin gene. J Biol Chem 1992; 267 (32) 23237-47. 16 Kwok S, Kellogg DE, McKinney N. et al. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 1990; 18 (04) 999-1005. 17 O’Dell SD, Gaunt TR, Day IN. SNPgenotyp-ing by combination of 192-well MADGE, ARMS and computerized gel image analysis. Biotechniques 2000; 29 (03) 500-6. 18 Day IN, Humphries SE. Electrophoresis for genotyping: microliter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994; 222 (02) 389-95. 19 Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility. Atheroscler Thromb Vase Biol. 2004 (hi press). 20 Man-Vague I, Morange PE, Aubert H. et al. On behalf of the HIFMECH Study group. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen concentration and TAFI genotype in relation to myocardial infarction in the North and South of Europe. Atheroscler Throm Vase Biol 2002; 22: 867-73. 21 Chakravarti A, Buetow KH, Antonarakis SE. et al. Nonuniform recombination within the human beta-globin gene cluster. Am J Hum Genet 1984; 36 (06) 1239-58. 22 Kern PA, Saghizadeh M, Ong JM. et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95 (05) 2111-9. 23 Yudkin JS, Stehouwer CD, Emeis JJ. et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vase Biol 1999; 19 (04) 972-8. 24 Yudkin JS. Relationship of serum C3 complement with insulin resistance and coronary heart disease-cause, consequence or common antecedent?. Eur Heart J 2000; 21 (13) 1036-9. 25 Ziccardi P, Nappo F, Giugliano G. et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105 (07) 804-9. 26 Mendall MA, Patel P, Asante M. et al. Relation ofserumcytokineconcentrationstocardiovas-cular risk factors and coronary heart disease. Heart 1997; 78 (03) 273-7. 27 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73 (01) 159-65. 28 Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and post-transcriptional mechanisms. Blood 1991; 77 (03) 542-50. 29 Speiser W, Kapiotis S, Kopp CW. et al. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 2001; 85 (02) 362-7.
